{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:50:59Z","timestamp":1785865859185,"version":"3.56.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA077598"],"award-info":[{"award-number":["P30 CA077598"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA288972"],"award-info":[{"award-number":["R37CA288972"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-2-0025"],"award-info":[{"award-number":["W81XWH-22-2-0025"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["PF-23-1153194-01-CDP"],"award-info":[{"award-number":["PF-23-1153194-01-CDP"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human leukocyte antigen (HLA) class I encompasses peptide-binding proteins that regulate T-cell interactions. We examined HLA class I expression in prostate cancers (PC), exploring associations with clinical outcomes, molecular features, and tumor immune microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 8040 PC samples from the Caris Life Sciences database, stratifying them into HLA-high (upper quartile) and -low (lower quartile) groups. Genomic and transcriptomic alterations were compared. Immune cell fractions were inferred using quanTIseq, and overall survival (OS) data was obtained from insurance claims. Differences were computed with Cox proportional hazards.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 66 cancer types, PC ranked 3\n                      <jats:sup>rd<\/jats:sup>\n                      -, 11\n                      <jats:sup>th<\/jats:sup>\n                      -, and 19\n                      <jats:sup>th<\/jats:sup>\n                      -lowest for HLA-A, -B, and -C expression, respectively. In PC, genes tied to androgen receptor (\n                      <jats:italic>AR<\/jats:italic>\n                      ) signaling, immune checkpoint molecules (\n                      <jats:italic>CTLA4, PD-L1<\/jats:italic>\n                      ), and the epithelial-mesenchymal transition were significantly higher in HLA-high tumors. HLA-high status was linked to greater tumor immune activity, marked by higher T cell fractions and enhanced immune hallmarks. HLA-high tumors were less likely to possess alterations in\n                      <jats:italic>AR, FOXA1<\/jats:italic>\n                      , and\n                      <jats:italic>CDK12<\/jats:italic>\n                      , but harbored increased alterations in tumor suppressor gene (\n                      <jats:italic>RB1<\/jats:italic>\n                      ,\n                      <jats:italic>PTEN<\/jats:italic>\n                      ) alterations. Tumors with high HLA-A and HLA-B had elevated TMB-H\/MSI-H\/dMMR status. Finally, shorter OS was observed in patients with high HLA-A or HLA-B expression, while longer OS was associated with high HLA-C expression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In PC, elevated HLA class I levels correlate with immune activity, molecular characteristics, and clinical outcomes. We suggest considering HLA expression as a supplementary marker of immune activity in PC, alongside genetic mutations and transcriptomic markers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-025-01045-9","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T13:42:37Z","timestamp":1761399757000},"page":"425-434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancer"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-3851","authenticated-orcid":false,"given":"Pornlada","family":"Likasitwatanakul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6586-800X","authenticated-orcid":false,"given":"Carissa","family":"Besonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4014-1946","authenticated-orcid":false,"given":"Alexander K.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Sadeghipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali T.","family":"Arafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Passow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Chesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Felices","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0239-5440","authenticated-orcid":false,"given":"Philippa R.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8205-738X","authenticated-orcid":false,"given":"Vivek","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hamrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-9546","authenticated-orcid":false,"given":"Laura A.","family":"Sena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7021-968X","authenticated-orcid":false,"given":"Nicholas A.","family":"Zorko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin H.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0031-9655","authenticated-orcid":false,"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"1045_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1045_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1045_CR3","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw JNCCN. 2023;21:1067\u201396.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"1045_CR4","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1200\/JCO.23.00155","volume":"41","author":"KS Virgo","year":"2023","unstructured":"Virgo KS, Rumble RB, Talcott J. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. J Clin Oncol. 2023;41:3652\u20136.","journal-title":"J Clin Oncol"},{"key":"1045_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.euf.2016.11.013","volume":"2","author":"D Tilki","year":"2016","unstructured":"Tilki D, Schaeffer EM, Evans CP. Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor. Eur Urol Focus. 2016;2:499\u2013505.","journal-title":"Eur Urol Focus"},{"key":"1045_CR6","doi-asserted-by":"publisher","first-page":"9887","DOI":"10.1073\/pnas.1402468111","volume":"111","author":"HT Kissick","year":"2014","unstructured":"Kissick HT, Sanda MG, Dunn LK, Pellegrini KL, On ST, Noel JK, et al. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc Natl Acad Sci. 2014;111:9887\u201392.","journal-title":"Proc Natl Acad Sci"},{"key":"1045_CR7","doi-asserted-by":"publisher","first-page":"14565","DOI":"10.1073\/pnas.251140998","volume":"98","author":"M Mercader","year":"2001","unstructured":"Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA. 2001;98:14565\u201370.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1045_CR8","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1056\/NEJM200009073431006","volume":"343","author":"J Klein","year":"2000","unstructured":"Klein J, Sato A. The HLA System. N Engl J Med. 2000;343:702\u20139.","journal-title":"N Engl J Med"},{"key":"1045_CR9","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017;171:1259\u201371.e11.","journal-title":"Cell"},{"key":"1045_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","volume":"359","author":"D Chowell","year":"2018","unstructured":"Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359:582\u20137.","journal-title":"Science"},{"key":"1045_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","volume":"11","author":"M Montesion","year":"2021","unstructured":"Montesion M, Murugesan K, Jin DX, Sharaf R, Sanchez N, Guria A, et al. Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response. Cancer Discov. 2021;11:282\u201392.","journal-title":"Cancer Discov"},{"key":"1045_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, et al. Neoantigen directed immune escape in lung cancer evolution. Nature. 2019;567:479\u201385.","journal-title":"Nature"},{"key":"1045_CR13","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1200\/JCO.23.00233","volume":"41","author":"ES Antonarakis","year":"2023","unstructured":"Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, et al. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. J Clin Oncol J Am Soc Clin Oncol. 2023;41:3839\u201350.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"1045_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41525-024-00392-1","volume":"9","author":"HE Bergom","year":"2024","unstructured":"Bergom HE, Sena LA, Day A, Miller B, Miller CD, Lozada JR, et al. Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer. Npj Genom Med. 2024;9:1\u20139.","journal-title":"Npj Genom Med"},{"key":"1045_CR15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","volume":"606","author":"X Guan","year":"2022","unstructured":"Guan X, Polesso F, Wang C, Sehrawat A, Hawkins RM, Murray SE, et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature. 2022;606:791\u20136.","journal-title":"Nature"},{"key":"1045_CR16","doi-asserted-by":"crossref","unstructured":"Chesner LN, Polesso F, Graff JN, Hawley JE, Smith AK, Lundberg A, et al. Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer. Cancer Discov 2025;15:481\u201394.","DOI":"10.1158\/2159-8290.CD-24-0559"},{"key":"1045_CR17","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","volume":"30","author":"A Szolek","year":"2014","unstructured":"Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O. OptiType: precision HLA typing from next-generation sequencing data. Bioinforma Oxf Engl. 2014;30:3310\u20136.","journal-title":"Bioinforma Oxf Engl"},{"key":"1045_CR18","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.humimm.2013.06.025","volume":"74","author":"L Gragert","year":"2013","unstructured":"Gragert L, Madbouly A, Freeman J, Maiers M. Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry. Hum Immunol. 2013;74:1313\u201320.","journal-title":"Hum Immunol"},{"key":"1045_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/bioinformatics\/btz474","volume":"36","author":"R Orenbuch","year":"2020","unstructured":"Orenbuch R, Filip I, Comito D, Shaman J, Pe\u2019er I, Rabadan R. arcasHLA: high-resolution HLA typing from RNAseq. Bioinforma Oxf Engl. 2020;36:33\u201340.","journal-title":"Bioinforma Oxf Engl"},{"key":"1045_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1374087","volume":"14","author":"S Dawood","year":"2024","unstructured":"Dawood S, Natarajan V, Danchaivijitr P. Comprehensive molecular profiling identifies actionable biomarkers for patients from Thailand and the United Arab Emirates with advanced malignancies. Front Oncol. 2024;14:1374087.","journal-title":"Front Oncol"},{"key":"1045_CR21","doi-asserted-by":"crossref","unstructured":"Hwang J, Likasitwatanakul P, Deshmukh SK, Wu S, Kwon JJ, Toye E et al. Structurally-oriented classification of FOXA1 alterations identifies prostate cancers with opposing clinical outcomes and distinct molecular and immunologic subtypes. Clin Cancer Res. 2025;31:936\u201348.","DOI":"10.1158\/1078-0432.CCR-24-3471"},{"key":"1045_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"1045_CR23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference. Nat Methods. 2017;14:417\u20139.","journal-title":"Nat Methods"},{"key":"1045_CR24","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1045_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0638-6","volume":"11","author":"F Finotello","year":"2019","unstructured":"Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019;11:34.","journal-title":"Genome Med"},{"key":"1045_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B Methodol. 1995;57:289\u2013300.","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"1045_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s13238-020-00786-8","volume":"12","author":"M Teng","year":"2021","unstructured":"Teng M, Zhou S, Cai C, Lupien M, He HH. Pioneer of prostate cancer: past, present and the future of FOXA1. Protein Cell. 2021;12:29\u201338.","journal-title":"Protein Cell"},{"key":"1045_CR28","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrc3263","volume":"12","author":"KM Jozwik","year":"2012","unstructured":"Jozwik KM, Carroll JS. Pioneer factors in hormone-dependent cancers. Nat Rev Cancer. 2012;12:381\u20135.","journal-title":"Nat Rev Cancer"},{"key":"1045_CR29","doi-asserted-by":"publisher","first-page":"5631","DOI":"10.1158\/0008-5472.CAN-14-0476","volume":"74","author":"C Geng","year":"2014","unstructured":"Geng C, Rajapakshe K, Shah SS, Shou J, Eedunuri VK, Foley C, et al. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res. 2014;74:5631\u201343.","journal-title":"Cancer Res"},{"key":"1045_CR30","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116:11428\u201336.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1045_CR31","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"R Dan","year":"2015","unstructured":"Dan R, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215\u201328.","journal-title":"Cell"},{"key":"1045_CR32","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41391-017-0027-4","volume":"21","author":"BL Maughan","year":"2018","unstructured":"Maughan BL, Guedes LB, Boucher K, Rajoria G, Liu Z, Klimek S, et al. p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2018;21:260\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1045_CR33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41391-021-00430-4","volume":"25","author":"MG Velez","year":"2022","unstructured":"Velez MG, Kosiorek HE, Egan JB, McNatty AL, Riaz IB, Hwang SR, et al. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:479\u201383.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1045_CR34","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"Bono","year":"2020","unstructured":"Bono, de J, Mateo J, Fizazi K, Saad F, Shore N, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382:2091\u2013102.","journal-title":"N Engl J Med"},{"key":"1045_CR35","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487\u201395.","journal-title":"Cancer Discov"},{"key":"1045_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37874-2","volume":"14","author":"V Bhatia","year":"2023","unstructured":"Bhatia V, Kamat NV, Pariva TE, Wu L-T, Tsao A, Sasaki K, et al. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat Commun. 2023;14:2041.","journal-title":"Nat Commun"},{"key":"1045_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3390\/cancers14030503","volume":"14","author":"MPJ Perera","year":"2022","unstructured":"Perera MPJ, Thomas PB, Risbridger GP, Taylor R, Azad A, Hofman MS, et al. Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. Cancers. 2022;14:503.","journal-title":"Cancers"},{"key":"1045_CR38","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.clgc.2022.07.009","volume":"21","author":"G Mjaess","year":"2023","unstructured":"Mjaess G, Aoun F, Rassy E, Diamand R, Albisinni S, Roumegu\u00e8re T. Antibody-Drug Conjugates in Prostate Cancer: Where Are we?. Clin Genitourin Cancer. 2023;21:171\u20134.","journal-title":"Clin Genitourin Cancer"},{"key":"1045_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2024.2356820","volume":"25","author":"J Palecki","year":"2024","unstructured":"Palecki J, Bhasin A, Bernstein A, Mille PJ, Tester WJ, Kelly WmK, et al. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer. Cancer Biol Ther. 2024;25:2356820.","journal-title":"Cancer Biol Ther"},{"key":"1045_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/17562872231182219","volume":"15","author":"KK Zarrabi","year":"2023","unstructured":"Zarrabi KK, Narayan V, Mille PJ, Zibelman MR, Miron B, Bashir B, et al. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer. Ther Adv Urol. 2023;15:17562872231182219.","journal-title":"Ther Adv Urol"},{"key":"1045_CR41","first-page":"115","volume":"25","author":"XC Wang","year":"2006","unstructured":"Wang XC, Zhang JQ, Shen YQ, Miao FQ, Xie W. Loss of heterozygosity at 6p21.3 underlying HLA class I downregulation in gastric cancer. J Exp Clin Cancer Res CR. 2006;25:115\u20139.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"1045_CR42","first-page":"2741","volume":"12","author":"X Zhao","year":"2011","unstructured":"Zhao X, Sun Q, Tian H, Cong B, Jiang X, Peng C. Loss of heterozygosity at 6p21 and HLA class I expression in esophageal squamous cell carcinomas in China. Asian Pac J Cancer Prev APJCP. 2011;12:2741\u20135.","journal-title":"Asian Pac J Cancer Prev APJCP"},{"key":"1045_CR43","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/PPO.0b013e31823b042c","volume":"17","author":"NE Martin","year":"2011","unstructured":"Martin NE, Mucci LA, Loda M, DePinho RA. Prognostic Determinants in Prostate Cancer. Cancer J Sudbury Mass. 2011;17:429\u201337.","journal-title":"Cancer J Sudbury Mass"},{"key":"1045_CR44","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41416-021-01400-2","volume":"125","author":"E Schaafsma","year":"2021","unstructured":"Schaafsma E, Fugle CM, Wang X, Cheng C. Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy. Br J Cancer. 2021;125:422\u201332.","journal-title":"Br J Cancer"},{"key":"1045_CR45","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<472::AID-CNCR27>3.0.CO;2-0","volume":"85","author":"IJ Powell","year":"1999","unstructured":"Powell IJ, Banerjee M, Sakr W, Grignon D, Wood DP, Novallo M, et al. Should African-American men be tested for prostate carcinoma at an earlier age than white men?. Cancer. 1999;85:472\u20137.","journal-title":"Cancer"},{"key":"1045_CR46","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S0090-4295(96)00618-8","volume":"49","author":"IJ Powell","year":"1997","unstructured":"Powell IJ, Heilbrun LK, Sakr W, Grignon D, Montie J, Novallo M, et al. The predictive value of race as a clinical prognostic factor among patients with clinically localized prostate cancer: a multivariate analysis of positive surgical margins. Urology. 1997;49:726\u201331.","journal-title":"Urology"},{"key":"1045_CR47","doi-asserted-by":"crossref","unstructured":"Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, et al. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J Clin Invest. 2019;129:e123791.","DOI":"10.1172\/JCI123791"},{"key":"1045_CR48","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/s41416-020-0834-6","volume":"122","author":"T Vidotto","year":"2020","unstructured":"Vidotto T, Melo CM, Castelli E, Koti M, dos Reis RB, Squire JA. Emerging role of PTEN loss in evasion of the immune response to tumours. Br J Cancer. 2020;122:1732\u201343.","journal-title":"Br J Cancer"},{"key":"1045_CR49","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.cancergen.2014.09.003","volume":"207","author":"JL Williams","year":"2014","unstructured":"Williams JL, Greer PA, Squire JA. Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data. Cancer Genet. 2014;207:474\u201388.","journal-title":"Cancer Genet"},{"key":"1045_CR50","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways. Am J Clin Oncol. 2016;39:98\u2013106.","journal-title":"Am J Clin Oncol"},{"key":"1045_CR51","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41391-024-00797-0","volume":"28","author":"NA Zorko","year":"2025","unstructured":"Zorko NA, Makovec A, Elliott A, Kellen S, Lozada JR, Arafa AT, et al. Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes. Prostate Cancer Prostatic Dis. 2025;28:129\u201337.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1045_CR52","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-24-0060","volume":"30","author":"MC Dallos","year":"2024","unstructured":"Dallos MC, Obradovic AZ, McCann P, Chowdhury N, Pratapa A, Aggen DH, et al. Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer. Clin Cancer Res J Am Assoc Cancer Res. 2024;30:5218\u201330.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"1045_CR53","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-19-3372","volume":"26","author":"A Obradovic","year":"2020","unstructured":"Obradovic A, Dallos MC, Zahurak ML, Partin AW, Schaeffer EM, Ross AE, et al. T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. Clin Cancer Res J Am Assoc Cancer Res. 2020;26:3182\u201392.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"1045_CR54","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.cell.2017.09.050","volume":"171","author":"R Marty","year":"2017","unstructured":"Marty R, Kaabinejadian S, Rossell D, Slifker MJ, van de Haar J, Engin HB, et al. MHC-I Genotype Restricts the Oncogenic Mutational Landscape. Cell. 2017;171:1272\u201383.e15.","journal-title":"Cell"},{"key":"1045_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00743-4","volume":"12","author":"AM Goodman","year":"2020","unstructured":"Goodman AM, Castro A, Pyke RM, Okamura R, Kato S, Riviere P, et al. MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Med. 2020;12:45.","journal-title":"Genome Med"},{"key":"1045_CR56","doi-asserted-by":"publisher","unstructured":"Yamaguchi H, Hsu J-M, Sun L, Wang S-C, Hung M-C. Advances and prospects of biomarkers for immune checkpoint inhibitors. Cell Rep Med 2024; 5. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101621.","DOI":"10.1016\/j.xcrm.2024.101621"},{"key":"1045_CR57","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J Clin Oncol J Am Soc Clin Oncol. 2020;38:395\u2013405.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"1045_CR58","doi-asserted-by":"publisher","first-page":"e004115","DOI":"10.1136\/jitc-2021-004115","volume":"10","author":"T Michelakos","year":"2022","unstructured":"Michelakos T, Kontos F, Kurokawa T, Cai L, Sadagopan A, Krijgsman D, et al. Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer. J Immunother Cancer. 2022;10:e004115.","journal-title":"J Immunother Cancer"},{"key":"1045_CR59","doi-asserted-by":"publisher","first-page":"e000375","DOI":"10.1136\/jitc-2019-000375","volume":"8","author":"H Matsushita","year":"2020","unstructured":"Matsushita H, Hasegawa K, Oda K, Yamamoto S, Asada K, Karasaki T, et al. Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma. J Immunother Cancer. 2020;8:e000375.","journal-title":"J Immunother Cancer"},{"key":"1045_CR60","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/sj.bjc.6605315","volume":"101","author":"M Shehata","year":"2009","unstructured":"Shehata M, Mukherjee A, Deen S, Al-Attar A, Durrant LG, Chan S. Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy. Br J Cancer. 2009;101:1321\u20138.","journal-title":"Br J Cancer"},{"key":"1045_CR61","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/bjc.2013.696","volume":"110","author":"ECM Zeestraten","year":"2014","unstructured":"Zeestraten ECM, Reimers MS, Saadatmand S, Dekker J-WT, Liefers GJ, van den Elsen PJ, et al. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. Br J Cancer. 2014;110:459\u201368.","journal-title":"Br J Cancer"},{"key":"1045_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06300-3","volume":"9","author":"KG Paulson","year":"2018","unstructured":"Paulson KG, Voillet V, McAfee MS, Hunter DS, Wagener FD, Perdicchio M, et al. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun. 2018;9:3868.","journal-title":"Nat Commun"},{"key":"1045_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24890-3","volume":"12","author":"S-H Han","year":"2022","unstructured":"Han S-H, Kim M, Chung YR, Woo JW, Choi HY, Park SY. Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer. Sci Rep. 2022;12:20367.","journal-title":"Sci Rep"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01045-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01045-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01045-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:04:58Z","timestamp":1779343498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01045-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1045"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01045-9","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JH consults for Tempus and Astrin Biosciences and is a co-founder of EMRGNSE. ESA reports grants and personal fees from Janssen, Sanofi, Bayer, Bristol Myers Squibb, Curium, Merck, Pfizer, AstraZeneca, Clovis, Constellation; personal fees from Astellas, Amgen, Blue Earth, Exact Sciences, Invitae, Eli Lilly, and Foundation Medicine; grants from Novartis, Celgene, and grants from Orion outside the submitted work; and has a patent for an AR-V7 biomarker technology that has been licensed to Qiagen. Other co-authors report no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}